A Breakthrough in Triple-Negative Breast Cancer Treatment: Sacituzumab Govitecan Offers Hope Where Options Were Limited
Imagine facing a diagnosis of advanced triple-negative breast cancer, a particularly aggressive form of the disease, only to be told that standard treatments like PD-1/PD-L1 inhibitors aren't an option for you. This is the reality for many patients, but a recent study brings a glimmer of hope. The phase 3 ASCENT-03 trial has revealed that sacituzumab govitecan, a novel therapy, significantly extends progression-free survival (PFS) in these patients, offering a much-needed alternative.
But here's where it gets even more promising: This isn't just about buying a little more time; it's about potentially changing the course of treatment for a significant portion of patients.
In this open-label trial, 558 patients with locally advanced or metastatic triple-negative breast cancer, ineligible for PD-1/PD-L1 inhibitors, were randomly assigned to receive either sacituzumab govitecan or standard chemotherapy chosen by their doctor. The results were striking. Patients on sacituzumab govitecan experienced a median PFS of 9.7 months, compared to 6.9 months for those on chemotherapy – a difference that’s both statistically significant and clinically meaningful.
And this is the part most people miss: While the objective response rates were similar between the two groups (48% vs. 46%), the duration of response was notably longer with sacituzumab govitecan (12.2 months vs. 7.2 months). This means not only are patients living longer without their cancer worsening, but their responses to treatment are lasting longer, too.
Importantly, the safety profile of sacituzumab govitecan was comparable to chemotherapy, with both groups experiencing similar rates of severe side effects (66% vs. 62%). The most common side effects included neutropenia (low white blood cell count), diarrhea, anemia, and leukopenia (low white blood cell count). Interestingly, fewer patients on sacituzumab govitecan discontinued treatment due to side effects (4% vs. 12% for chemotherapy), suggesting it may be better tolerated in the long run.
Dr. Cortes and colleagues concluded that sacituzumab govitecan offers a significant PFS advantage over chemotherapy for patients with advanced triple-negative breast cancer who cannot receive PD-1 or PD-L1 inhibitors. While adverse events were common, they were manageable and comparable to those seen with standard chemotherapy.
But here’s the controversial part: Should sacituzumab govitecan now be considered the new standard of care for this patient population? While the results are compelling, some may argue that longer-term follow-up is needed to fully understand its impact on overall survival and quality of life.
What do you think? Is this a game-changer for triple-negative breast cancer treatment, or do we need more data before making it the go-to option? Share your thoughts in the comments below.
Source:
Cortes J, Punie K, Barrios C, et al. Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. N Engl J Med. Published online: October 18, 2025. doi:10.1056/NEJMoa2511734
Disclaimer:
The views and opinions expressed herein are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
Related Content:
- Rebecca Dent, MD, discusses the phase 3 TROPION-Breast02 trial, comparing datopotamab deruxtecan to chemotherapy in metastatic triple-negative breast cancer.
- Stephanie Holland reports on the BEGONIA study, highlighting the promise of datopotamab deruxtecan plus durvalumab in advanced triple-negative breast cancer.
- Sonya Reid, MD, MPH, and Seth Wander, MD, provide insights into the latest advancements in oncology.
